Syndax Pharmaceuticals (SNDX) Accounts Payables (2015 - 2026)

Syndax Pharmaceuticals' Accounts Payables history runs 12 years deep, the most recent figure standing at $10.8 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 7.92% year-over-year to $10.8 million; the TTM figure through Mar 2026 stood at $10.8 million (up 7.92% YoY), while the FY2025 annual figure was $16.6 million, up 42.61% from the prior year.
• Accounts Payables was $10.8 million for Q1 2026 at Syndax Pharmaceuticals, down from $16.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $17.4 million in Q2 2025 to a low of $4.4 million in Q4 2022.
• Historically, Accounts Payables has averaged $9.8 million across 5 years, with a median of $10.0 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables retreated 23.27% in 2022, then soared 182.28% in 2025.
• A 5-year view of Accounts Payables shows it stood at $4.4 million in 2022, then soared by 128.99% to $10.0 million in 2023, then increased by 16.72% to $11.6 million in 2024, then surged by 42.61% to $16.6 million in 2025, then slumped by 34.6% to $10.8 million in 2026.
• The last three Accounts Payables figures came in at $10.8 million (Q1 2026), $16.6 million (Q4 2025), and $13.8 million (Q3 2025), per Business Quant data.